Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin

Atsuhiro Ichihara1, Yuki Kaneshiro, Mariyo Sakoda

  • 1Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. atzichi@sc.itc.keio.ac.jp

Insights

Adding amlodipine to angiotensin II type 1 receptor blockers (ARBs) improved vascular function and structure in hypertensive patients. These benefits occurred independently of blood pressure reduction, suggesting amlodipine

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Hypertension poses significant cardiovascular risks.
  • Angiotensin II type 1 receptor blockers (ARBs) are common antihypertensives.
  • Further interventions are explored for patients with controlled blood pressure.

Purpose of the Study:

  • To assess if amlodipine improves cardiovascular damage in hypertensive patients already on ARBs.
  • To evaluate amlodipine's effects on vascular structure and function beyond blood pressure control.

Main Methods:

  • A 12-month, randomized, placebo-controlled trial.
  • Evaluated cardiothoracic ratio, urinary albumin, pulse wave velocity (PWV), intima-media thickness (IMT), and 24-hour ambulatory blood pressure (BP).
  • 50 hypertensive patients on ARB therapy received add-on amlodipine or placebo.

Main Results:

  • Add-on amlodipine significantly improved PWV and IMT.
  • No significant changes were observed in cardiothoracic ratio or urinary albumin excretion.
  • Amlodipine reduced ambulatory BP variability, but this did not mediate vascular improvements.

Conclusions:

  • Low-dose amlodipine offers vascular benefits in ARB-treated hypertensive patients, independent of blood pressure reduction.
  • Amlodipine's antiatherogenic properties may prevent arterial stiffness progression.
  • This suggests a role for amlodipine in comprehensive hypertensive management.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...